Kornimate/medical-research-clean huggingface dataset:
combining stellate ganglion and t2 and t3 radiofrequency ablation on post-mastectomy complex regional pain syndrome

Conditions: Stellate Ganglion; Radiofrequency Ablation; Complex Regional Pain Syndromes; Mastectomy

Summary: the aim of this study is to evaluate the efficacy of the combination of ultra sound (us) guided radiofrequency stellate ganglion block (sgb) and radiofrequency thoracic paravertebral block (tpvb) comparing to us-guided sgb or tpvb alone on the post-mastectomy pain syndrome (pmps).

breast cancer is the most common malignancy among females, with an incidence of about 2.1 million women each year. it is the most common cause of cancer-related deaths among women. modified radical mastectomy (mrm) is one of the main surgical treatments for breast cancer. it accounts for 31% of all breast surgery cases. nearly 40-60% of breast surgery patients experience severe acute postoperative pain, with severe pain persisting for 6-12 months in almost 20-50% of patients (post-mastectomy pain syndrome. complex regional pain syndrome (crps) is a clinical diagnosis with a highly variable presentation and prognosis. crps type i, previously known as reflex sympathetic dystrophy (rsd), is not associated with direct nerve injury. crps type ii, or causalgia, is associated with direct injury of a specific nerve, often from surgical intervention or trauma. symptoms include severe pain, sensitivity to light touch, burning, sweating, skin discoloration, edema, temperature changes, loss of motor function, and decreased range of motion of the affected limb. the mechanism of crps is not fully understood with central and peripheral sensitization involved.

Eligibility criteria:
inclusion criteria: * female patients. * type of surgery: modified radical mastectomy mrm. * physical status asa ii, iii. * duration of more than 6 months and less than 2 years. * moderate and severe pain (visual analog scale \[vas\] ≥ 40 mm). * pain described as a refractory to strong opioids (oxycodone) and adjuvant therapy such as(pregabalin) for which more invasive interventions could be tried. exclusion criteria: * patient refusal. * patient with local and systemic sepsis. * local anatomical distortion. * history of contralateral chest disease or pneumonectomy. * known sensitivity or contraindication to the drug used in the study. * history of psychological disorders. * contraindication to regional anesthesia, e.g., pre-existing peripheral neuropathies and coagulopathy. * severe respiratory or cardiac disorders. advanced liver or kidney disease. * pregnancy. * physical status asa iv and male patients.
a study of the efficacy and safety of tocilizumab in participants with systemic sclerosis (ssc)

Conditions: Systemic Sclerosis

Summary: this study will assess the efficacy and safety of tocilizumab compared with placebo in participants with ssc across approximately 120 planned global study sites. the study will consist of a 48-week, double-blind, placebo-controlled period followed by a 48-week open-label treatment period. participants will be assigned, in a 1:1 ratio, to double-blind treatment with active tocilizumab or matching placebo. in the open-label period, eligible participants from either arm may receive active tocilizumab.


Eligibility criteria:
inclusion criteria: * diagnosis of ssc according to american college of rheumatology (acr) and european league against rheumatism (eular) criteria, meeting criteria for active disease and with total disease duration of less than or equal to (\</=) 60 months * mrss of 10-35 units, inclusive * agreement to remain abstinent or use an effective contraceptive method among males and females with childbearing potential exclusion criteria: * pregnant or lactating females * major surgery within 8 weeks prior to screening * scleroderma limited to the face or areas distal to the elbows or knees * rheumatic autoimmune disease other than ssc * immunization with a live or attenuated vaccine within 4 weeks prior to baseline * known hypersensitivity to human, humanized, or murine monoclonal antibodies * moderately severe nervous system, renal, endocrine, pulmonary, cardiovascular, or gastrointestinal (gi) disease not related to ssc, including diverticulitis or ulcerative lower gi disorders, or myocardial infarction (mi) within 6 months prior to screening * active or significant history of infection, including treatment with intravenous (iv) antibiotics within 4 weeks or oral antibiotics within 2 weeks prior to screening * significant history of tuberculosis (tb) * primary or secondary immunodeficiency * malignant disease, with the exception of excised/cured local basal or squamous cell carcinoma of the skin or carcinoma in situ of the uterine cervix * history of drug or alcohol abuse
the effect of zhen qi shen capsule combined with yu yi kang on breast cancer and lung cancer patients with chemotherapy

Conditions: Breast Cancer; Lung Cancer

Summary: the purpose of this study is to research more reasonable and safe methods of nutritional support to improve the nutritional status of tumor patients, which guarantees the anti-tumor treatment such as chemotherapy.

this study is a prospective, randomized, controlled clinical trials. 300 patients were randomly divided into 2 groups for its own control study. test group: zhen qishen capsule (2 capsules, bid) and oral supplement of yuyikang (50g,bid), a total of 150 people, are used for 42 days continuously. placebo group: zhen qishen capsule placebo (2 capsules, bid) and oral supplement of yuyikang placebo (50g, bid), a total of 150 people, are used for 42 days continuously. the subjects were randomized to ab or ba parallely, and the two groups were given chemotherapy and nutrition.

Eligibility criteria:
inclusion criteria: * patients aged between 18 and 70 years old * breast or lung cancer was diagnosed by pathology or cytology * ecog score: 0-2 points * pg-sga: 2-8 points, while the weight loss within 3 months less than 5% * the organ function is good, with chemotherapy index. anc is equal to or over 1.5 \* 10\^9/l, plt is equal to or over 100\* 10\^9/l, hgb is equal to or over 90g/l * bilirubin is equal to or less than 1.5 times of the normal upper limit, ap, ast, alt is less than or equal to 2 times of normal upper limit * ccr is equal to or over 50ml/min * life expectancy is equal to or over 12 weeks exclusion criteria: * complete or incomplete intestinal obstruction * a severe infection or difficult to control diabetes * history of organ transplantation, or current use of immunosuppressive agents * an intervention in nutritional supplements, or a metabolic disorder * parenteral nutrition must be applied * alcoholism or drug addiction * pregnancy or lactation, or women of childbearing age refuse contraception * there are potential factors that interfere with the mental, psychological, family, social or geographical and other factors of the research project * there are other diseases that may interfere with the results of this study, such as the second primary tumor * for any other reason, the researchers were unable to complete the study

Keywords: breast cancer lung cancer nutritional support safety effectiveness
activating and connecting teens (act) study

Conditions: Depression

Summary: national data indicate over 650,000 children and adolescents are exposed to physical, sexual, or emotional abuse or physical or emotional neglect each year. moreover, youth with a history of childhood maltreatment (cm) are at least twice as likely to develop depression and are at substantial risk for nonresponse to current best practice depression interventions (i.e., cognitive behavioral therapy and antidepressants) compared to non-maltreated peers. research suggests that cm increases risk for depression through disruptions in the positive valence system, such as reward processing, and behavioral activation (ba) may be an alternative depression intervention that targets these deficits. this proposal will examine whether ba intervention reduces depression and anhedonia in a sample of depressed adolescents, aged 13-18, with variable histories of cm exposure (ba group). a total of 30 depressed adolescents will be recruited to undergo a 12-week course of ba. all participants will undergo clinical assessment to measure depression symptoms and anhedonia at baseline (week 0) and post- (week 12) treatment.


Eligibility criteria:
inclusion criteria behavioral activation group: - current diagnosis of clinical depression (minor or major) will be recruited as study participants in the behavioral activation (ba) group exclusion criteria: * iq \< 80; * non-english speaking youth or parent; * current ptsd diagnosis; * lifetime history of a developmental (e.g., autism), neurological (e.g., epilepsy), psychotic, bipolar, or substance disorder; * current psychiatric (e.g., antidepressants) or other mood altering medication (e.g., steroids) other than ad/hd medication; * requiring a higher level of care (i.e., inpatient hospitalization) due to suicidality or other mental or physical health related problem. * any youths who are currently being maltreated will not be enrolled to ensure that participants do not have active safety concerns. * full course of other evidence-based depression intervention

Keywords: depression childhood adversity behavioral activation reward processing
re-invitation to screening colonoscopy: a randomized study

Conditions: Colorectal Cancer; Screening; Patient Participation

Summary: the aim of this study is to compare the effect of reminding letter and educational intervention on attendance to screening colonoscopy in nonresponders to initial invitation to screening colonoscopy.

nordicc (the nordicc initiative on colorectal cancer, nct00883792) is a multicenter randomised trial to investigate the effect of screening colonoscopy on crc incidence and mortality. in poland, in warsaw area, at least 10,000 subjects 55-64 years of age are to be invited to screening colonoscopy. a personal letter of invitation containing date and hour of appointment is mailed to every individual randomised to the screening group. up to 60% of invitees do not respond to the initial invitation and reminding letter. the aim of this study is to compare the effect of reminding letter and educational intervention on attendance to screening colonoscopy in nonresponders to initial invitation to screening colonoscopy.

Eligibility criteria:
inclusion criteria: * men and women 55-64 years of age invited for screening colonoscopy within the nordicc trial (nct00883792) in poland, who have not responded to the first invitation. exclusion criteria: * resident abroad * return of unopened letter of invitation and/or reminder (address unknown) * message from neighbour/family/post office on death of screenee (not updated in population registry).

Keywords: colorectal cancer screening colonoscopy attendance participation
creating a virtual village for people aging with hiv during covid-19

Conditions: Hiv; Depression in Old Age; Isolation, Social; Aging

Summary: in a pcori-funded project on hiv and aging engagement that was co-led by the study team, the topics of isolation and depressions were identified as priority areas of deep concern among older plwh. the covid-19 pandemic has enhanced the urgency to test interventions to mitigate depression and isolation among older plwh. however, there is scant evidence on effective interventions that help mitigate depression and isolation among older plwh. while physical distancing and stay at home orders are a necessary strategy to flatten the curve, ease pressure on the healthcare system, and protect the most vulnerable, the order further increases the isolation faced by people aging with hiv, and creates barriers to accessing medications, health services, and other resources. this project will include 6 virtual focus groups and 12 individual interviews with adults ages 50 or older in california (palm spring, los angeles) and the tampa-bay region, florida to (1): further characterize issues related to depression, isolation, and basic needs of people aging with hiv during the covid-19 pandemic (2) utilizing results from aim 1, co-develop ideas for what to include in a virtual village, and (3) create and pilot the virtual village in a group of people aging with hiv. the overall goal of this study is to execute an innovative solution to address issues related to isolation for older plwh which have been exacerbated during the covid-19 pandemic.


Eligibility criteria:
inclusion criteria: * english or spanish speaking adults * living with hiv * residing in palm springs, los angeles, or tampa bay florida * age 50 or older exclusion criteria: * not able to read english or spanish
atrial fibrillation ablation on gastric motility "the af gut study"

Conditions: Atrial Fibrillation Ablation Procedure

Summary: you are being scheduled to undergo an ablation procedure to treat your atrial fibrillation. complications of ablation procedures include damage to structures near the heart from the heat energy used during the ablation procedure. these complications include damage to the esophagus (the tube through which food passes when you swallow) and stomach. a rare but often fatal complication resulting from severe heat damage is called an atrio-esophageal fistula (an abnormal connection between the heart and esophagus). however, the frequency of minimal damage to the esophagus or nerves of the gut that may go unnoticed are not known. this study is designed to determine how often atrial fibrillation ablation causes problems with the stomach and esophagus.


Eligibility criteria:
inclusion criteria: * all patients aged 18 years or more who undergo pulmonary vein isolation with radiofrequency ablation for clinically indicated atrial fibrillation. exclusion criteria: 1. patients with established diagnosis of esophageal or gastric function abnormalities. 2. patients who are unable to give consent or major psychiatric condition not under control. 3. patients who had abdominal surgical procedures on stomach, esophagus or pancreas (esophagectomy, gastrostomy, gastrectomy (billroth i, billroth ii, roux-en-y), bariatric surgery \[gastric bypass surgery, adjustable gastric band, sleeve gastrectomy, vertical banded gastroplasty surgery\], gastroenterostomy, hill repair, nissen fundoplication, gastropexy, pancreatectomy, pancreaticoduodenectomy, pancreas transplantation, vagotomy). 4. patients who unable to undergo any of the above mentioned procedures namely, esophageal manometry or sham feeding test or scientigraphy gastric emptying scan. 5. patients with chronic pancreatitis. 6. patients with either acute or chronic neuropathies such as diabetic, inflammatory, autoimmune and cranial neuropathies effecting vagal nerve or gastroparesis or achalasia. limited peripheral neuropathies such as carpal tunnel syndrome or isolated bell's palsy can be included. 7. patients who have undergone previous radiofrequency ablation for atrial fibrillation or patients who had history of either minimally invasive or invasive or maze or modified maze procedures for atrial fibrillation.
pulsed paclitaxel and daily thoracic radiotherapy for inoperable (stage i/ii) or unresectable lung cancer

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: a treatment study is being conducted by the university of rochester cancer center (urcc) in which patients with non-small cell lung cancer will be treated with radiation therapy and a drug called paclitaxel. paclitaxel is a natural product with anticancer properties. the first purpose of this study is to determine the dose of paclitaxel which, when given in combination with radiation therapy, will provide the greatest effect have the least side effects. to determine this, patients will be put on the study in groups of 3. the dose for each additional group will be higher than the previous dose until the maximum tolerated dose is reached. the second purpose is to determine if radiation therapy with paclitaxel is more effective in treating lung cancer than radiation therapy alone.


Eligibility criteria:
inclusion criteria: * histologically confirmed lung cancer, excluding small cell carcinoma * inoperable stage i (t1-2n0) and ii (t1-2n1, t3n0) disease, or stage iiia (t3n1 andt1-3n2m0) and iiib (txn3m0, t4nxm0) diseases according to the american joint committee of cancer criteria 1998 * the primary tumor must be radiographically measurable. * age \> 18. * karnofsky performance status \> 70. * fev1 sufficient for patients to tolerate radiation therapy which is at the discretion of the radiation oncologist, usually \> 800 ml * labs: wbc \> 3000; platelet count \> 100,000; serum creatinine \ 60 ml/min. * laboratory values must be obtained \< 3 weeks prior to registration. * a signed informed consent. * patients who failed prior chemotherapy are eligible. patients with prior radiotherapy to the chest region are eligible as long as the normal tissue tolerance is not violated by repeat radiotherapy. exclusion criteria: * patients with medical contraindication to chemotherapy or radiotherapy. * patients with myocardial infarction within the preceding six months or symptomatic heart disease, including uncontrolled or unstable angina, uncontrolled congestive heart failure, and uncontrolled arrhythmia. * women who are pregnant. * patients with small cell carcinoma or mesothelioma
growth arrest in focal dermal hypoplasia

Conditions: Focal Dermal Hypoplasia

Summary: focal dermal hypoplasia (fdh) is a rare genetic disorder of ectodermal dysplasia caused by mutation in the porcupine homolog (drosophila) (porcn) gene which results in skin, hair, limb and eye abnormalities. short stature and underweight have been noted in the majority of these patients. since the pituitary gland arises from ectodermal tissue, the investigators suspect that pituitary deficiencies may contribute to poor linear growth. this study will examine the nutritional, gastrointestinal and endocrine mechanisms that may account for linear growth stunting and low weight that is observed in fdh. the investigators will utilize standard clinical tools including a bone age xray, glucagon stimulation test to evaluate growth hormone status, baseline laboratory analysis of hormone and nutritional/gastrointestinal markers, food diaries, symptom diaries, and growth charts.

focal dermal hypoplasia (fdh) is a rare genetic disorder of ectodermal dysplasia caused by mutation in the porcupine homolog (drosophila) (porcn) gene which results in skin, hair, limb and eye abnormalities. short stature and underweight have been noted in the majority of these patients. since the pituitary gland arises from ectodermal tissue, the investigators suspect that pituitary deficiencies may contribute to poor linear growth. this study will examine the nutritional, gastrointestinal and endocrine mechanisms that may account for linear growth stunting and low weight that is observed in fdh. the investigators will utilize standard clinical tools including a bone age xray, glucagon stimulation test to evaluate growth hormone status, baseline laboratory analysis of hormone and nutritional/gastrointestinal markers, food diaries, symptom diaries, and growth charts.

Eligibility criteria:
inclusion criteria: * patients with focal dermal hypoplasia * between the ages of 3 and 18 years * ability to fast overnight, and * weight at least 9 kg exclusion criteria: * pregnant individuals, * weight less than 9 kg
effects of soy isoflavones on menopausal hot flashes

Conditions: Menopausal Symptoms

Summary: hot flashes occur in three quarters of menopausal women, and can negatively impact quality of life. interest has arisen in isoflavones, found in rich supply in soy products, as therapy for hot flashes. the study examines the effect of a new soy supplement, as compared to a placebo, in menopausal women on hot flash symptoms.

hot flashes occur in 75% of menopausal women and impact quality of life. interest has arisen in isoflavones, found in rich supply in soy products, as therapy for hot flashes. the effect of a daidzein-rich isoflavone-aglycone supplement from soy germ fermentation with koji fungus, on the severity and frequency of hot flashes in postmenopausal women is being examined in a randomized, placebo controlled, double-blinded clinical trial. the study is a 13 week trial in which subjects record their hot flash frequency and severity in a diary. subjects are given 40 mg or 60 mg of isoflavones (or placebo) once a day. this isoflavone-aglycone extract (agly-max tm, nichimo, shinagawa, tokyo, japan) is a product prepared from soybean germ fermentation with koji fungus (aspergliius awamori) producing ß-glycosidase efficiency, followed by ethanol and water extraction and purification by using a proprietary extraction procedure. the product is rich in daidzein (70% daidzein, 10% genistein, and 20% glycitein).

Eligibility criteria:
inclusion criteria: no menstrual period for at least six months, hot flashes at least four t imes per day, ages 38-65 exclusion criteria: pregnant, bmi\>45, history of breast cancer or other estrogen dependent tumors, abnormal uterine bleeding, heart, renal, or liver disease, diabetes, women taking hormone replacement therapy or serotonin reuptake inhibitors, women taking any dietary supplements for the treatment of hot flashes (ex. soy supplements, vitamin e, flaxseed, red clover extract) within the past 30 days

Keywords: hot flashes menopausal symptoms soybean germ aglycones menopause
transnasal induction of normothermia in febrile stroke patients

Conditions: Stroke, Ischemic; Stroke Hemorrhagic; Fever; Seizures; Metabolic Encephalopathy

Summary: the objective of this study is to evaluate safety and performance of the coolstat® transnasal thermal regulating device in reducing temperature in a population of febrile subjects who meet the inclusion/exclusion criteria.


Eligibility criteria:
inclusion criteria: 1. admitted to the neurosciences critical care unit (nccu). 2. patient has ischemic or hemorrhagic stroke, seizure, or metabolic encephalopathy. 3. patient is orally intubated or has tracheostomy tube and is mechanically ventilated. 4. planned stay in nccu \> 24 hours. 5. must have informed consent from the patient or the legally authorized representative (lar) exclusion criteria: 1. age \ 95 years. 2. intubation is contraindicated. 3. with a coagulopathy. inr above 1.5 or ptt above 45 seconds. 4. hemodynamic instability, including elevated spb for \>5 minutes despite standard of care interventions (spb ≥ 160 mmhg for intracerebral hemorrhagic stroke; spb ≥ 220 mmhg for subarachnoid hemorrhagic stroke or ischemic stroke). 5. history of cryoglobulinemia. 6. history of sickle cell disease. 7. history of serum cold agglutinin disease. 8. active/ongoing of nose bleeds. 9. known or suspected pregnancy. 10. participation in another ongoing investigational study. 11. prisoners and/or patients for whom no lar is available. 12. patient is in airborne/droplet disease isolation protocol. 13. patient is or suspected to be immunocompromised; 14. low platelet count defined as \< 100k (thrombocytopenia). 15. nasal septal deviations (per ct scan; any degree). 16. chronic rhinosinusitis. 17. prior skull-based surgery 18. penetrating cranial trauma. 19. recent nasal trauma or anterior base skull fracture. 20. presence of cardiac arrhythmias including: sustained tachycardia defined as heart rate above 120 beats per minute, or sustained bradycardia defined as heart rate below 60 beats per minute. 21. refractory hypoxemia defined as partial pressure of oxygen in arterial blood (pao2) below 60 torr or oxyhemoglobin saturation below 90% despite endotracheal intubation, mechanical ventilation, and provision of supplemental oxygen of up to 0.60. 22. refractory hypercarbia defined as partial pressure of carbon dioxide in arterial blood (paco2) above 50 torr despite endotracheal intubation and conventional mechanical ventilation. 23. history of cardiac arrhythmia as listed above. 24. bmi of ≤ 15 kg/m2 or ≥ 40kg/m2

Keywords: shivering, fever, normothermia